Back to
Boston Trust Walden Corp
HAE
31 quarters
Position history for
Boston Trust Walden Corp's holdings in Haemonetics Corporation
Yes. Boston Trust Walden holds 385,355 shares of HAE (Haemonetics), worth $40.6M, as of its Q3 2026 13F filing. It reduced the position by 199,793 shares (-34.1%) from Q2 2026. Boston Trust Walden has held HAE in every 13F on record since Q1 2019, 31 quarterly filings. HAE is 0.3% of Boston Trust Walden's reported 13F portfolio.
Current Value
$40.6M
Current Shares
385,355
Total Value Change
+$30.1M
Total Shares Change
+265,763
Quarter-by-Quarter History
Other major holders of HAE: Wellington Management Group LLP, Capital Research Global Investors